EU Approves AZN Etcamah for ESR1 Breast Cancer; FDA Follows in September

The European Commission approved AstraZeneca’s (AZN) Etcamah (camizestrant) on July 23, 2026, for first-line treatment of ER-positive, HER2-negative locally advanced or metastatic breast cancer in patients whose tumors develop an emergent ESR1 mutation during endocrine therapy. The approval pairs camizestrant with any of the three approved CDK4/6 inhibitors: palbociclib (Ibrance), ribociclib (Kisqali), or abemaciclib (Verzenio).

Etcamah is the 11th new AstraZeneca medicine of the 20 the company expects to launch by 2030. AZN closed at $169.26 on July 24, with a market capitalization of roughly $262.5 billion.

The SERENA-6 data

The approval rests on the Phase 3 SERENA-6 trial, the first registrational study to use a ctDNA-guided approach in first-line breast cancer. Patients were monitored via blood test every 2 to 3 months. When an ESR1 mutation emerged without disease progression, patients were randomized to switch to camizestrant or continue the aromatase inhibitor, both maintaining the same CDK4/6 inhibitor.

At a planned interim analysis, 157 patients who switched to camizestrant achieved median PFS of 16.0 months (95% CI, 12.7 to 18.2) versus 9.2 months for 158 patients who continued the AI plus CDK4/6 inhibitor. That is a 56% reduction in the risk of disease progression or death (hazard ratio 0.44; p<0.00001). A subsequent analysis showed a statistically significant PFS2 benefit of 25.7 months. Overall survival data remain immature but trended in favor of camizestrant (HR 0.87).

What ESR1 mutation switching means

ESR1 mutations are the most common mechanism of acquired endocrine resistance in ER-positive breast cancer, arising in roughly 30% of patients on aromatase inhibitor therapy before disease progression. Historically, oncologists waited for radiographic progression before switching therapy. SERENA-6 tested a different premise: detect the resistance mutation in the blood before visible progression, then swap the endocrine agent while keeping the CDK4/6 backbone.

Camizestrant is a next-generation oral SERD and complete ER antagonist. Unlike fulvestrant, which requires intramuscular injection, camizestrant is a once-daily oral pill at 75 mg that degrades both wild-type and mutant estrogen receptors.

The US regulatory split

Update September 4, 2026: The FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor, overriding the ODAC’s 6-to-3 vote against. See our article on the US approval.

The FDA initially held out. On April 30, 2026, the agency’s Oncologic Drugs Advisory Committee (ODAC) voted 6 to 3 against camizestrant’s benefit-risk profile, and the FDA extended the PDUFA date to December 2026 to review updated SERENA-6 results. The EU approval, along with prior approvals in Japan, the UAE, and Saudi Arabia, put regulatory pressure on the FDA but did not bind it. On September 4, 2026, the FDA cleared the drug on an accelerated basis, roughly three months early.

For readers tracking FDA decision deadlines, see our guide to PDUFA dates.

Competitive positioning

The first-line ER-positive, HER2-negative breast cancer market is dominated by CDK4/6 inhibitors paired with endocrine therapy. Pfizer’s Ibrance, Novartis’s Kisqali, and Lilly’s Verzenio collectively generate over $13 billion in annual revenue. Camizestrant complements them, approved alongside any of the three. The opportunity is the roughly 30% of patients who develop ESR1 mutations on AI therapy.

AstraZeneca’s breast cancer franchise already includes Enhertu, the HER2-directed ADC partnered with Daiichi Sankyo. Etcamah broadens it into endocrine resistance.

Risks

With US accelerated approval secured, the remaining risk shifts to confirmatory data. Overall survival remains immature. If the final OS fails to show a survival advantage, payer enthusiasm could wane and the accelerated approval could be reconsidered. Competition from Elacestrant (Stemline), an oral SERD already approved for ESR1-mutated disease in later lines, limits the later-line opportunity.

What to watch next

Confirmatory trial data and the final overall survival readout. The FDA cleared camizestrant on progression-free survival; continued approval hinges on verification of clinical benefit in confirmatory studies.

AstraZeneca press release | Onclive SERENA-6 coverage